Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients

First patients dosed in Phase IIa study of novel GLP-2 peptide agonist

06-Mar-2012 - Denmark

Zealand Pharma A/S and Helsinn announced that the first patients have been dosed in a Phase IIa study of elsiglutide (ZP1846) for the prevention of chemotherapy-induced diarrhea in cancer patients. Elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) agonist invented by Zealand Pharma and licensed to Helsinn.

The Phase IIa study is a randomized, double-blind and placebo-controlled proof-of-concept study to assess the efficacy and safety of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID) in colorectal cancer patients receiving 5-fluorouracil (5-FU)-based chemotherapy. In the study, elsiglutide is administered subcutaneously in parallel with 5-FU. The Phase IIa study is conducted by Helsinn and plans to enroll 138 cancer patients in approximately 20 centers across European countries.

Helsinn is also completing a Phase Ib study of elsiglutide in Europe under an Investigational New Drug (IND) with the US Food and Drug Administration (FDA) so far showing that the drug candidate is safe and well tolerated at doses above the expected therapeutic dose in colorectal cancer patients.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Alzheimer’s: modulation of cell membrane influences formation of amyloid-β - Adding long-chain fatty acids can thicken cell membranes and alter the activity of a key enzyme

Alzheimer’s: modulation of cell membrane influences formation of amyloid-β - Adding long-chain fatty acids can thicken cell membranes and alter the activity of a key enzyme

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

Agilent Technologies Opens Global Manufacturing Facility for Life Sciences Instruments

New targeting opportunities discovered against canine distemper virus - Structure of the canine distemper virus "docking protein" determined and depicted it at molecular level for the first time - and this can also help with measles

New targeting opportunities discovered against canine distemper virus - Structure of the canine distemper virus "docking protein" determined and depicted it at molecular level for the first time - and this can also help with measles

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Novartis study showed ACZ885 provided substantial symptom relief in 84% of patients with the most serious form of childhood arthritis - Second pivotal Phase III trial ongoing; worldwide regulatory submissions planned for 2012

Organ bioprinting gets a breath of fresh air - Bioengineers clear major hurdle on path to 3D printing replacement organs

Organ bioprinting gets a breath of fresh air - Bioengineers clear major hurdle on path to 3D printing replacement organs

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

In neurodegenerative diseases, brain immune cells have a “ravenous appetite” for sugar - The interpretation of certain brain scans needs rethinking

In neurodegenerative diseases, brain immune cells have a “ravenous appetite” for sugar - The interpretation of certain brain scans needs rethinking

Low levels of natural antibodies behind stroke

Cell Medica strengthens team with key appointment to senior management

A toxic bullet involved in bacterial competition

A toxic bullet involved in bacterial competition